Citius Oncology, Inc. CTOR PHARMA
Company Overview
Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. operates as a subsidiary of Leonard-Meron Biosciences, Inc.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.25.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -48.09% |
| 6 Months: | -8.01% |
| 3 Months: | +16.14% |
| 1 Month: | +23.39% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)68.07 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 57.2% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CTOR Citius Oncology, Inc. PHARMA | 0.93 | -1.94 | $98.36M | 0.00% | -45.72% | -126.58% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2021 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | 3.94M | 1.67M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | 3.15M | 1.34M |
| Operating Income | - | - | - | -147.92K | -199.55K | -421.45K | - | -268.43K | -4.63M | -6.39M | -7.47M | -4.94M | -5.25M | -28.61M |
| Net Income | -724 | - | - | 611.73K | 616.30K | 157.94K | -4.73M | -4.84M | -4.77M | -6.66M | -7.74M | -5.37M | -5.53M | -26.61M |
| Diluted EPS | - | 0.00 | 0.00 | 0.07 | 0.07 | 0.02 | -0.07 | -0.07 | -0.07 | -0.09 | -0.11 | -0.08 | -0.06 | -0.27 |
| R&D Expense | - | - | - | - | - | - | 1.15M | 1.35M | 1.13M | 1.26M | 3.14M | 938.28K | 1.02M | 1.08M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Sep 2022 | Dec 2022 | Sep 2023 | Dec 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | - | 0 | - | 0 | - | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - |
| Operating Expenses | - | 4.86M | - | 12.12M | - | 20.57M | 23.52M |
| Operating Income | -10.11K | -4.86M | -138.12K | -12.12M | -1.01M | -20.57M | -23.52M |
| EBITDA | - | -4.86M | - | -12.12M | - | -20.57M | -23.49M |
| Interest Expense | - | - | - | - | - | 0 | 218.03K |
| Pretax Income | - | -4.86M | - | -12.12M | - | -20.57M | -23.70M |
| Tax Provision | - | 576.00K | - | 576.00K | - | 576.00K | 1.06M |
| Net Income | -10.11K | -5.43M | 380.81K | -12.70M | 2.42M | -21.15M | -24.76M |
| Diluted EPS | - | -0.08 | 0.12 | -0.18 | 0.27 | -0.31 | -0.34 |
| R&D Expense | - | - | - | 4.24M | - | 4.93M | 6.42M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Sep 2022 | Dec 2022 | Sep 2023 | Dec 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | 126.42K | - | 68.19M | 47.73M | 72.62M | 84.37M | 100.94M |
| Total Equity | -10.11K | 36.27M | 345.51K | 25.54M | -1.99M | 46.14M | 44.87M |
| Total Liabilities | - | - | - | 22.20M | - | 38.23M | 56.08M |
| Current Liabilities | 136.53K | - | 31.84K | 21.05M | 2.05M | 32.70M | 49.49M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|
| Operating Cash Flow | -47.97K | -601.30K | 126.35K | -5.49M |
| Investing Cash Flow | -67.32M | -1.32M | -5.00M | -5.75M |
| Financing Cash Flow | 67.66M | 1.66M | 4.87M | 15.17M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Sep 2022 | Dec 2022 | Sep 2023 | Dec 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - |
| ROE % | 100.0% | -15.0% | 110.2% | -49.7% | -121.7% | -45.8% | -55.2% |
| ROCE % | 100.0% | - | -0.2% | -45.4% | -1.4% | -39.8% | -45.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Armistice Capital, LLC | 9.36% | 8.71M | $9.92M |
| 2 | Bank of America Corporation | 4.12% | 3.84M | $4.37M |
| 3 | Vanguard Capital Management LLC | 0.59% | 546.33K | $622.81K |
| 4 | UBS Group AG | 0.36% | 334.62K | $381.46K |
| 5 | Geode Capital Management, LLC | 0.26% | 245.41K | $279.76K |
| 6 | Vanguard Fiduciary Trust Co | 0.13% | 121.91K | $138.98K |
| 7 | IFP Advisors, Inc | 0.12% | 107.42K | $122.46K |
| 8 | Citadel Advisors Llc | 0.10% | 90.59K | $103.27K |
| 9 | State Street Corporation | 0.05% | 42.90K | $48.91K |
| 10 | Northern Trust Corporation | 0.05% | 45.75K | $52.15K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CTOR
Citius Pharma CEO to speak at two New York conferences - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxPVFBnd0tUUkZJMFVLeXBaTXJFbk9kQjlRYllzaF9sZ1RTN242SlhuR2xKT0F0ZmJ1b29zY20zdFZweWFBckR4NXpkcV9wcnpISVhpQktvN2ttQjN0aGNaR3hUNkxrQmVtdWs4UjZVMzFuOWZ5UlJ3Vmw2NjQ1bEVzMmhEbDlsZkdLNExNYn…
Breakeven On The Horizon For Citius Oncology, Inc. (NASDAQ:CTOR) - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi4gFBVV95cUxPNjNzQzhKRlAyS0NlQVpLYlgwVzJGVFlFSjN1ZFlFaVlnSnN1V3ZMSGFnVVVIdjJnT0hfbDFGblNLRlhRUWdzNE12VHpSWURDUWpfa2lJTU41akt0eTNPMDVvdG5ldk56T1VEaTJxa1dKdmtHQXV1dWgwbXFPTjlYcGVkNmNQRmV4Rkh3QV…
Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update - PR Newswire
<a href="https://news.google.com/rss/articles/CBMi7gFBVV95cUxQdDVVYXRySHpab0tWbjYxN3lMblY4dUEwMUNrNV9xLTYyYnVaTXMySXZURnNIeEk3eDA2bEhleGg5UUpndzd1TEFtaEp2bm91THdsMmdSX2ZFcU5ITFc0V3lyaV8xcVVEeWtDN1UtMHYtYjMwQk4yZmdHMjFkQ0VYVzBOZDZoZ0hfNzBnQj…
CTOR - Citius Oncology Inc Stock Price and Quote - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTFBKc1dUX3lSWW9kdXdIYXpsdnpLZG5OWVpDbHdTbzM1RUs3b3ExQmJRNE5FcldUTzRFbjV3WS1hako2THJlMFE?oc=5" target="_blank">CTOR - Citius Oncology Inc Stock Price and Quote</a> <font co…
Citius Oncology shares tumble as Q3 revenue misses forecasts despite LYMPHIR launch momentum - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxNcnh3LU8yVTUzcXJ0YkN0d1dfU1hoZ1dGNGRfV2FCR1cwNkhId1U5ZnBPMjZ2eVlKb1ZUTTU0ajVZbVVIeE0zQnhLV09fN1FQR3lpOVZENzVqcVZBNGRIQ09wOFNpSk5feEtKbzFMRXZVRzdMM0xCNGlvY3J1cDVLc1JDYXpWYWRYMzZMTm…
CTOR Stock Price and Chart — NASDAQ:CTOR - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiXEFVX3lxTFBfb19pMzljR0tOTlRqWkNrSHpNRUUzS2RLdlFWSEVLeEFkQW1FcUlZZl8yV1FBVUtreW9icUw3ZC1IcEVhNVhWOFdtdk1JUUdnRUY2UG5EWGRzbXNJ?oc=5" target="_blank">CTOR Stock Price and Chart — NASDAQ:CTOR</a…
CTOR — Frequently Asked Questions
What is the current share price of Citius Oncology, Inc. (CTOR)?
As of 2026-09-19 21:16 PDT, Citius Oncology, Inc. (CTOR) trades at $0.93 on NasdaqCM. Its 52-week range is $0.49 to $2.17.
What is the market capitalisation of CTOR?
Citius Oncology, Inc. (CTOR) has a market capitalisation of $98.36M on NasdaqCM.
What is the P/E ratio of CTOR?
CTOR trades at a trailing price-to-earnings (P/E) ratio of -1.94. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 2.46.
What is the return on equity (ROE) of CTOR?
CTOR has a return on equity (ROE) of -126.58%. Its return on capital employed (ROCE) is -45.72%.
Is CTOR a good stock to buy?
This page provides a data-driven analysis of Citius Oncology, Inc. (CTOR), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.